Craft

HitGen

Revenue

¥523.7 M

FY, 2025

HitGen Summary

Company Summary

Overview
HitGen (成都先导药物开发股份有限公司) is a biotech company providing a platform for small molecule drug discovery research. It focuses on the design, synthesis, and screening of DNA-encoded chemical libraries (DELs). The company specializes in a range of therapeutic areas, including oncology, cardiovascular, respiratory, metabolism, and other diseases.
Type
Public
Status
Active
Founded
2012
HQ
Chengdu, CN | view all locations
Website
https://www.hitgen.com/en
Cybersecurity rating
Sectors

Key People

  • Guansai Liu

    Guansai Liu, Vice President of Discovery Chemistry Unit

  • Dengfeng Dou

    Dengfeng Dou, Vice President of Lead Generation Unit

  • Xiaodong Huang

    Xiaodong Huang, Chief Development Officer, Discovery Projects Unit

  • Hongge Liu

    Hongge Liu, Chief Financial Officer

    LocationsView all

    2 locations detected

    • Chengdu, Si Chuan Sheng HQ

      China

      Building C2, NO.8, Huigu 1st East Road Tianfu International Bio-Town, Shuangliu District

    • Cambridge, England

      United Kingdom

      Granta Park, Great Abington

    HitGen Financials

    Summary Financials

    Revenue (Q1, 2026)
    ¥160.1M
    Gross profit (Q1, 2026)
    ¥90.0M
    Net income (Q1, 2026)
    ¥41.5M
    Cash (Q1, 2026)
    ¥630.5M
    EBIT (Q1, 2026)
    ¥49.3M

    Footer menu